Background: To assess whether deletions involving codons 557 and/or 558 (critical deletions) of exon 11 of KIT are relevant in the prognosis of relapse-free survival (RFS) in gastrointestinal stromal tumor (GIST) patients with a long follow-up. (RR 8.12, and NDTM (RR 6.42, were independent prognostic factors for RFS. The median follow-up was 84 months.
introduction
The recognition of the oncogenic role of certain mutations within the KIT or PDGFR-a genes in most gastrointestinal stromal tumor (GIST) patients and the advent of effective target-based therapies to treat this disease, such as imatinib and other tyrosine kinase inhibitors, have led to consider GIST as an attractive model for the studies of several specialists including surgeons, radiologists, pathologists, molecular biologists and oncologists [1] .
Mitotic count and size are the most recognized prognostic factors in localized GIST [2, 3] . Indeed, a risk stratification index of primary tumors was developed on the basis of these parameters and published in 2002 by Fletcher et [5] , from Armed Forces Institute of Pathology (AFIP), on the basis of the long-term follow-up of >1600 patients (M-L/AFIP) and incorporating tumor location as an important factor. Surgery is the mainstay treatment in localized disease. However, even when microscopically free surgical margins are obtained (R0), recurrence ranges from 20%-55% [6] [7] [8] [9] [10] . Treatment with imatinib has dramatically changed expectations on response rates, progression-free survival and overall survival in metastatic patients [11, 12] .
In recent years, there has been special interest in exploring prognostic factors at the molecular level for localized GIST and thus, some papers have assessed the potential relevance of mutations on prognosis [13] [14] [15] [16] [17] . Our group found, in a series of 162 localized GIST patients, that deletions involving codons 557-558 (DEL 557-558) within exon 11 of the KIT gene had an independent prognostic value for relapse-free survival (RFS) [18] .
We planned three main objectives in the current study: to assess whether DEL 557-558 still has prognostic relevance after a longer follow-up period, to evaluate whether DEL 557-558 still serves as an independent prognostic factor for RFS in conjunction with the new M-L/AFIP risk categories, and finally, to explore whether there is a time-dependent prognostic variable for RFS in GIST patients.
patients and methods

patients and study design
The selection of a final subset of 162 patients after a clinical and pathological review (paraffin blocks) of 357 cases has been explained previously [18] . The current update was carried out through a query-based task applied to each patient at risk of recurrence, and it involved data managers and clinical oncologists. The patients have been followed through clinical examination and abdominal computed tomography on a regular basis since 2001.
clinical and mutational prognostic variables
The clinical and pathological variables considered in the RFS analysis included the F/NIH risk classification and M-L/AFIP risk classification (Table 1) .
To increase the sensitivity of the mutational analysis, those cases in which no mutation was detected by direct sequencing were then screened by denaturing high-performance liquid chromatography (DHPLC) in a Transgenomic WAVE DNA Fragment Analysis System (Transgenomic, Inc., Omaha, NE).
Mutations were studied within the following groups: deletions involving codons 557 and/or 558 (henceforth referred to as critical mutations), presence of KIT gene mutations, deletions within exon 11 of the KIT gene and those cases with non-deletion-type mutation within exon 11 of the KIT gene (missense and duplication-type mutations). This latter aggregation was chosen for comparison and was justified as each type of mutation had a tendency to cluster.
statistical methods
The RFS was measured from the date of surgery and it was estimated according to the Kaplan-Meier method [19] . A multivariate analysis was carried out using the Cox proportional hazards model [20] . Survival analysis was carried out over the entire follow-up period, over the interval covering the first 4 years and for that from 4 years after surgery. In this way, the time-dependence weighting of the variables could be evaluated.
results
clinical data and the distribution of mutations in the patients
Clinical and pathological characteristics are depicted in Table 1 . Four novel mutations were found by the DHPLC screening resulting in a total of 100 mutated cases.
survival analyses for the entire time period
The median follow-up for the patients that remained free of recurrence after the current update was 84 months, with an actuarial RFS rate at 7 years of 68%. There were 48 events of recurrence, and 16 patients died by causes unrelated to GIST and without evidence of relapse. Table 2 depicts in detail the outcome of the univariate analyses. Several aggregations of mutations were analyzed and those patients harboring a critical mutation displayed the worst 7-year RFS (34%; Table 2 and Figure 1 ).
time-dependence survival analyses
We chose the 4-year time cut-off as it marked clearer differences with a sufficiently large follow-up including at least one-third of the main relevant original mutational subsets. This defined two different time periods: the 0-to 4-year aftersurgery interval (41 recurrences in 162 patients at risk) and >4 years (7 recurrences in 105 patients at risk). Considering the 105 patients at risk beyond 4 years, the median follow-up of the nonrelapsing patients was 49 months (4-126). Nine of the initial 25 (36%) patients with critical mutations and 23 of the initial 35 (66%) patients with non-deletion-type mutations were at risk of recurrence after 4 years from surgery. Median follow-up beyond 4 years were 50 months (21-98) and 46 months (22-94) for critical and non-deletion-type mutations within exon 11, respectively.
Considering the molecular variables, critical mutations appeared to be significant and strong predictors of RFS, either for the entire follow-up period or for the 0-to 4-year interval. Nevertheless, it was noteworthy that critical mutations were no longer of prognostic relevance beyond the 4-year time interval. Conversely, the patients carrying non-deletion-type mutations within exon 11 still developed recurrences beyond 3 or 4 years after surgery (Table 2 and Figure 1) .
Factors independently associated with recurrence for the entire follow-up period were identical to those seen in the first 4 years after surgery, i.e. the M-L/AFIP risk categories (intermediate and high) and critical deletions. Taking into account the multivariate analysis for the time interval beyond 4 years after surgery, only the high-risk M-L/AFIP category and duplication or missense mutation type within exon 11 of the KIT gene were independent prognostic factors for RFS (Table 3) .
discussion
The M-L/AFIP risk criteria are powerful and they strongly discriminate three different subsets of patients according to their probability of recurrence, as demonstrated here and by others [21] .
Our results indicate the independent statistical value of critical mutations with a median follow-up of 7 years for localized GIST patients, the longest follow-up published to date that analyzed this molecular variable. Furthermore, we have demonstrated the independent significance of such mutations after confronting this factor with the current best risk classification criteria for locally resected GIST patients: the M-L/AFIP risk categories. Wardelmann et al. [22] found a significant correlation between metastases and the presence of critical mutations. Similarly, Iesalnieks et al. [23] detected an independent prognostic value of such critical deletions, in a multivariate analysis on a series of 35 patients in whom GIST was completely removed. More recently, Tzen, in a series of 101 GIST patients, concluded that there were no significant prognostic factors that involved the presence of any type of mutation. However, the analysis was of progression-free survival rather than RFS due to the inclusion of 43 patients (42% of cases) that either were unresectable or had metastatic tumors [24] . DeMatteo, in another recent article of 127 GIST patients submitted to complete gross surgical resection and followed up for a median of 5.2 years, found that a significant worse prognosis was associated with those patients carrying deletions involving codons 557 or 558. This result did not reach an independent value in the multivariate model despite showing a markedly poorer RFS curve, probably due to a high number of rectal cases included [25] . To our knowledge, few studies have addressed the time dependence of prognostic factors in sarcomas and none in the context of GIST [26] [27] [28] . The present analysis demonstrates that the prognostic significance of critical mutations is time dependent. Thus, their predictive value for recurrence is limited to the first 4 years after surgery and beyond 4 years, no patient harboring such mutations suffered a recurrence. Conversely, patients harboring non-deletion-type mutations within exon 11 had an adverse prognostic effect beyond the 4 years from surgery by maintaining their rate of relapses. Moreover, the high-risk category according to the M-L/AFIB criteria kept its negative impact value with the same relative risk (8.12) as that compared with the first 4-year time period (8.94).
Two further observations are worthy of consideration: on the one hand, tumors with DEL557 and/or 558 mutations showed no primary resistance in a series of 22 cases treated with imatinib [29] , while additionally, the frequency of DEL557 and/ or 558 mutations in localized GIST series is not inconsiderable, ranging from 15%-40% of the cases [18, 22, 25] . In conclusion, our findings could contribute to identify a subset of GIST patients with higher and earlier risk of relapse and irrespective of clinical prognostic factors. This would be the most suitable target population in which adjuvant tyrosine kinase inhibitors should be assessed to look for a significant impact on RFS. original article Annals of Oncology 
